Copyright
©2014 Baishideng Publishing Group Co.
World J Diabetes. Feb 15, 2014; 5(1): 69-75
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.69
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.69
Table 4 Hypoglycemia events n (%)
| LANMET | LANMETPLUS | DeGold | DeGoldPLUS | LANMET andLANMET PLUS | DeGold andDeGold PLUS | LANMETand DeGold | LANMET PLUSand DeGold PLUS | |
| Fixed initial dose | Variable initial dose | Fixed titration | Variable titration | |||||
| Patients with moderate or severe hypoglycemia (n) | 7 (27) | 6 (30) | 5 (22) | 5 (23) | 13 (28) | 10 (23) | 12 (25) | 11 (27) |
| Number of moderate or severe hypoglycemia events | 10 | 22 | 5 | 20 | 32 | 25 | 15 | 42 |
| Patients with symptomatic night hypoglycemia (n) | 13 (50) | 4 (15) | 5 (22) | 4 (19) | 17 (37) | 9 (20) | 18 (37) | 8 (19) |
| Number of nocturnal symptomatic hypoglycemia events | 46 | 16 | 9 | 8 | 62 | 17 | 31 | 25 |
| Patients presenting any type of hypoglycemia (n) | 16 (61) | 14 (70) | 15 (68) | 12 (57) | 30 (65) | 27 (62) | 31 (64) | 26 (60) |
| Number of any type of hypoglycemia events | 113 | 107 | 48 | 111 | 220 | 159 | 157 | 155 |
- Citation: Franco DR, Baptista J, Abreu FR, Batista RB, Eliaschewitz FG. Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe. World J Diabetes 2014; 5(1): 69-75
- URL: https://www.wjgnet.com/1948-9358/full/v5/i1/69.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i1.69